Refractory Neuroblastoma

Oncology·MeSH: Recurrence

Prevalence

30.0 / 100K

9 drugs in development·5 companies·4 clinical trials

Drug Pipeline by Phase

Phase 2(8)

Drug	Company
GM-CSF	UNITED THERAPEUTICS Corp (UTHR)
hu14.18K322A	Black Diamond Therapeutics, Inc. (BDTX)
hu14.18K322A	PTC THERAPEUTICS, INC. (PTCT)
hu14.18K322A	Filana Therapeutics Inc. (FLNA)
N803	PTC THERAPEUTICS, INC. (PTCT)
N803	Filana Therapeutics Inc. (FLNA)
N803	Black Diamond Therapeutics, Inc. (BDTX)
Sargramostim	PTC THERAPEUTICS, INC. (PTCT)

Phase 1(1)

Drug	Company
AUTO6NG	Autolus Therapeutics plc (AUTL)

BioSniper tracks 9 drugs in development for Refractory Neuroblastoma across 5 companies.

There are 4 clinical trials targeting Refractory Neuroblastoma tracked by BioSniper.

The estimated prevalence of Refractory Neuroblastoma is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.